We analyzed the clinical significance of pre-transplant International Prognostic Scoring System (IPSS) score and comorbidity in 68 patients who underwent allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndrome (MDS) (n ¼ 48) or acute myeloid leukemia evolved from MDS (n ¼ 20) between December 1995 and January 2008 in a single institute. During a median follow-up period of 41.0 months (range, 3.2-132.0 months), 27 patients died, and 7 relapsed. The 5-year probabilities of overall survival (OS) and event-free survival (EFS) were 60.0 and 57.4%, respectively, and the 5-year cumulative incidences of non-relapse mortality (CINRM) and relapse were 32.7 and 9.9%, respectively. OS, EFS, and CINRM were significantly different according to pre-transplant IPSS score and presence of pre-transplant comorbidity, which were independent risk factors along with Karnofsky performance score in multivariate analyses. In conclusion, pre-transplant IPSS score and comorbidity may stratify the risk of post transplant outcomes in MDS.
Introduction
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders, clinically characterized by peripheral cytopenias and evolution to acute leukemia. 1 Although several novel agents were recently introduced to treat MDS, allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment modality for this disease. [2] [3] [4] Large registries have reported overall survival (OS) rates of 41-42 and event-free survival (EFS) rates of 34-40% after 3-5 years in cases of HLA-identical sibling donor transplantation, 5, 6 and 2-year OS rates of 28-30 and EFS rates of 28-29% in patients receiving HCT from unrelated volunteer donors, 7, 8 with results from single centers reporting better survival rates. 9 Other sources of hematopoietic cell grafts have been investigated, including unrelated cord blood 10 and mismatched familial donors. 11 Relapse of disease and nonrelapse mortality are the main causes of failure after HCT for MDS and various prognostic factors, including age, disease duration, marrow blast percentage, and cyto genetics, may predict post transplant outcomes in MDS. 5, [12] [13] [14] [15] [16] The International Prognostic Scoring System (IPSS) was derived from a multivariate analysis of the hematologic characteristics of 816 patients at diagnosis of MDS. 17 This system, which is based on marrow blast percentage, cytogenetic findings, and number of cytopenias, has been found to estimate the likelihood of leukemic transformation and survival. [17] [18] [19] The IPSS has been also shown to predict the outcomes of HCT. 6, 9, 20, 21 Most of these studies, however, used IPSS score calculated at diagnosis and not at the time of HCT. With the recent availability of novel agents, such as epigenetic and immunomodulatory drugs, for the treatment of MDS, many patients receive one or two treatment regimens before HCT. Accordingly, post transplant outcomes may be more dependent on factors prevailing at the time of HCT than on data gathered at diagnosis. However, the ability of an IPSS score calculated at the time of HCT to predict post transplant outcomes has not yet been investigated.
Pre-transplant comorbidity, which was assessed using the HCT-specific comorbidity index (HCT-CI), was recently shown to be an independent predictor of HCT outcomes in patients with a variety of hematologic diseases. [22] [23] [24] In a study, HCT-CI scores and disease status could be used to stratify risk groups in patients with MDS and acute myeloid leukemia (AML) receiving allogeneic HCT. 25 In another study, HCT-CI and Karnofsky performance status are independent predictors of outcomes of allogeneic HCT after reduced-intensity conditioning. 26 The clinical significance of pre-transplant comorbidity, however, has been investigated in only a few institutes and experience with the HCT-CI in clinical practice is limited. We have, therefore, analyzed the clinical significance of pre-transplant IPSS score and comorbidity in patients who underwent allogeneic HCT for MDS or AML evolved from MDS in a single institute.
Patients and methods

Patients
Between December 1995 and January 2008, a total of 68 patients underwent allogeneic HCT for MDS (n ¼ 48) or AML evolved from MDS (n ¼ 20) at the Asan Medical Center, Seoul, Korea. Clinical and laboratory data on these patients were collected from the HCT database of the Asan Medical Center. Table 1 shows the WHO subtypes of MDS at diagnosis and those at the time of HCT. Of these patients, 35 (51.4%) at diagnosis and 46 (67.6%) at the time of HCT had advanced disease (refractory anemia of excess of blast [RAEB]-1, RAEB-2, or AML evolved from MDS). IPSS score was calculated at both times (Table 1) . Six patients had over 30% of bone marrow blasts at the time of HCT and the score for 20-30% of bone marrow blasts was applied when IPSS score was calculated for the patients. Twelve patients, who attained complete remission (CR) after chemotherapy, were classified in a 'Low' category at the time of HCT, regardless of the WHO subtype.
Patient characteristics and HCT information are given in Table 2 . The median age of the 68 patients, 44 males and 24 females, was 40 years (range, 19-63 years). Before HCT, 23 patients were given chemotherapy, composed of cytarabine plus duanorubicin to 17, cytarabine plus idarubicin to 4, and azacitidine to 2; of these, 12 patients attained CR, but 11 failed to achieve CR. Karnofsky performance score was 90 or more in 44 patients and o90 in 24 patients. The presence of pre-transplant comorbidity was evaluated by HCT-CI, which was recently modeled to effectively capture comorbidity and predict HCT outcomes. 23 HCT-CI scores could be assigned in 66 patients, of whom 22 (33%) had scores X1, including 15 with a score of 1, 3 with score of 2, 3 with a score of 3, and 1 with a score of 4. Cytogenetic analysis just before conditioning therapy revealed that 45 patients were in the good cytogenetic risk group by IPSS criteria 17 (including 42 with a normal karyotype, 2 with del(20q), and 1 with del(5q)), 4 were in the poor cytogenetic risk group (including 2 with del(7q) and 2 with a complex karyotype showing 3 or more abnormalities), and 19 were in the intermediate cytogenetic risk group having other abnormalities. The number of involved lineage(s) for cytopenia, which was defined as hemoglobin o10 g/100 ml, platelet count o1 00 000/ml, or neutrophil count o1800/ml, was 0 or 1 in 17 patients and 2 or 3 in 51 patients. The conditioning regimen was myeloablative in 40 patients (58.8%) and reduced-intensity conditioning in 28 (41.2%). Myeloablative conditioning regimens included BuCy (busulfan 4 mg/kg/day per oral or 3.2 mg/kg/day intravenously for 4 days plus cyclophosphadmide 60 mg/kg/day for 2 days) in 38 patients and BuFlu (busulfan for 4 days plus fludarabine 30 mg/m 2 /day for 5 days) in 2 patients. Reduced-intensity conditioning regimens included BuFluATG (busulfan for 2 days, fludarabine for 6 days plus antithymocyte globulin) in 24 patients and other regimens in 4 patients.
Definitions
The first day with an absolute neutrophil count over 500/ml for two consecutive days was recorded for bone marrow engraftment. Patients who did not display absolute neutrophil counts over 500/ml for two consecutive days after HCT, and who survived for at least 21 days, were classified as having experienced 'primary graft failure'. Patients with initial engraftment, but in whom absolute neutrophil counts subsequently declined to o500/ml, were classified as having experienced 'secondary graft failure'. The first day of unsupported platelet counts over 20 000/ml for 7 consecutive days was also recorded.
Acute and chronic graft-versus-host disease (GVHD) were diagnosed from clinical symptoms, laboratory tests, and, whenever possible, from histopathologic findings of the skin, oral mucosa, and gastrointestinal tract. 27, 28 Acute GVHD was classified according to clinical criteria 29 and chronic GVHD was graded as limited (localized skin or single organ involvement) or extensive (generalized skin or multiple organ involvement). 30 Statistical analysis OS and EFS were calculated from the date of HCT to time of death and event (relapse or death), respectively. Survival probabilities were calculated according to the KaplanMeier method and compared using the log-rank test. Cox proportional hazards regression model was used for multivariate analysis of independent prognostic factors for survival. 31 The cumulative incidences of relapse (CIR) and non-relapse mortality (CINRM), which were competing cause of failure for each other, 32 were calculated and compared using Gray's method. 33 The cumulative incidence of graft failure was also calculated using Gray's method and competing risk was relapse or death before graft failure.
Results
Engraftment data and major early post transplant toxicities An absolute neutrophil count over 500/ml was achieved in 64 of 68 patients on median day 16. Two patients died early after HCT and two experienced primary graft failure. Of the 68 patients, 57 achieved transfusion-independent platelet counts 420 000/ml on median day 29. Six patients experienced secondary graft failure 34-248 days after HCT. The cumulative incidence of graft failure (primary or secondary) was 12.0%.
Acute GVHD occurred in 22 (33.3%) of 66 evaluable patients; it was of grade I in 6 patients, grade II in 4, grade III in 7, and grade IV in 5. Chronic GVHD occurred in 34 (69.4%) of 49 evaluable patients; it was limited in 13 patients and extensive in 21. Thirty patients (44.1%) experienced cytomegalovirus infection, but only 5 developed cytomegalovirus disease. Interstitial pneumonitis occurred in 4 patients (5.9%) and hepatic veno-occlusive disease developed in 12 patients (17.7%), none of whom had severe disease.
Survival and relapse data
After a median follow-up of 41.0 months (range, 3.2-132.0 months) among surviving patients, 7 patients had relapsed and 27 had died. Of these, 21 deaths were not related to disease relapse, but were caused by engraftment failure (n ¼ 6), acute GVHD (n ¼ 6), chronic GVHD (n ¼ 4), interstitial pneumonitis (n ¼ 2), and other causes (n ¼ 3). The 5-year probabilities of OS and EFS were 60.0 and 57.4%, respectively, and 5-year CIR and CINRM were 9.9 and 32.7%, respectively.
Prognostic factor analysis
We evaluated 13 patient characteristics at the time of HCT, including IPSS score, comorbidity, and Karnofsky performance score as prognostic factors for post transplant outcomes, including OS, EFS, CIR, and CINRM. Table 3 shows the results of univariate analysis, in which statistically or marginally significant prognostic factors for post transplant outcomes were recipient gender (P ¼ 0.090 for OS), diagnosis (P ¼ 0.080 for CIR), disease status (P ¼ 0.027 for OS, P ¼ 0.011 for EFS, and P ¼ 0.062 for CINRM), Karnofsky performance score (P ¼ 0.009 for OS, P ¼ 0.019 for EFS, and P ¼ 0.011 for CINRM), comorbidity (P ¼ 0.001 for OS, P ¼ 0.001 for EFS, and P ¼ 0.009 for CINRM), IPSS score (P ¼ 0.002 for OS, P ¼ 0.003 for EFS, and P ¼ 0.023 for CINRM), transfusion dependency (P ¼ 0.045 for CINRM), and hematopoietic cell graft donor (P ¼ 0.081 for OS, P ¼ 0.059 for EFS, and P ¼ 0.086 for CIR). These variables were entered into appropriate multivariate models. Multivariate analysis showed that Karnofsky performance score, presence of pre-transplant comorbidity, and IPSS score at the time of HCT were significantly independent prognostic factors for OS, EFS, and CINRM, and hematopoietic cell donor was an independent prognostic factor for EFS (Table 4) . There was no independent prognostic factor for CIR. Influence of IPSS score at diagnosis was also analyzed and it was statistically or marginally significant for OS (P ¼ 0.060) and EFS (P ¼ 0.022) by univariate analysis, but its significance was lost during multivariate analysis. IPSS score at diagnosis was not significant for CINRM (P ¼ 0.242) or CIR (P ¼ 0.923). Categorization by the FAB or the WHO classification systems did not have significant influence on post transplant outcomes (data not shown). As both comorbidity and IPSS score at the time of HCT were independent prognostic factors for post transplant outcomes, we stratified the patients into three prognostic groups using these two variables: absence of comorbidity plus IPSS Low/Intermediate-1 category (group 1), presence of comorbidity or IPSS Intermediate-2/High category (group 2), and presence of comorbidity plus IPSS Intermediate-2/High category (group 3). Patients in group 1 showed the best outcomes with regard to OS, EFS, and CINRM, whereas those in group 3 had the poorest outcomes ( Figure 1 ) and patients in group 2 had intermediate outcomes. CIR did not differ significantly among the three groups.
Discussion
Although allogeneic HCT has curative potential for patients with MDS, the appropriate indications and optimal timing of transplantation have not been determined. 4, 34, 35 Classification systems such as the FAB 36 and WHO 37 categorizations and prognostic scoring systems such as the IPSS 17 and recently introduced WHO classification-based Prognostic Scoring System 19 have been used to select patients who might benefit from allogeneic HCT. Disease status can change over time because of disease progression or treatment. When disease status improves with treatment, subtypes by the FAB or WHO classification systems do not change, but the IPSS score can be recalculated. For example, a patient with RAEB-2 and in the IPSS 'High' risk category at diagnosis, but who achieves CR with chemotherapy before HCT, is still categorized as RAEB-2 by the WHO classification, whereas the IPSS score changes from the 'High' to the 'Low' category. Thus, compared with the classification systems, IPSS score may more accurately reflect changes in disease status. However, the prognostic value of IPSS scores recalculated after treatment has not been evaluated. Our study, in which 25 patients received chemotherapy before HCT, showed that IPSS score at the time of HCT is more prognostic of post transplant outcomes than is IPSS score at diagnosis or the WHO categorization. Pre-transplant IPSS score was a more powerful prognostic factor than disease status at the time of HCT (no prior treatment vs CR vs not in remission after treatment) or each component of IPSS (marrow blast percentage, cytogenetic findings, and number of cytopenias; data not shown). Our study results show that the IPSS score can be applied to the patients who already receive treatment and it should be recalculated at the time of HCT.
We also found that presence of comorbidity was strongly associated with higher CINRM, leading to significantly lower OS and EFS, thus confirming the prognostic significance of pre-transplant comorbidity, as assessed by the HCT-CI. However, we found that the distribution of HCT-CI scores differed from that in earlier studies by Sorror et al. 22, 23, 25 These studies reported that up to 58% of patients had HCT-CI scores X3, whereas we found that only 10% of our patients had scores X2, indicating the need for further evaluation of HCT-CI in various cohorts of patients because the incidence and severity of comorbidities may be different according to the inclusion criteria for HCT such as age, underlying disease, or intensity of conditioning regimens.
Performance status is an important outcome predictor after allogeneic HCT. 26, 38 Our study also showed that patients with high Karnofsky performance score (90 or more) had better post transplant outcomes (OS, EFS, and CINRM) than those with low score (80 or less). In multivariate analyses, each of pre-transplant IPSS score, presence of comorbidity, and Karnofsky performance score was independent prognostic factors for OS, EFS, and CINRM.
Main cause of failure in our study was non-relapse death rather than recurrence of disease and nearly half of non-relapse deaths were related to the development of Table 4 Multivariate analysis of prognostic factors for overall survival, even-free survival, and cumulative incidence of non-relapse mortality HR is the effect of the variable on the risk of an event that is death for overall survival, death or relapse for event-free survival, and non-relapse death for cumulative incidence of non-relapse mortality.
GVHD. Using a combination of pre-transplant IPSS score and comorbidity, our patients could be stratified into three prognostic groups. Patients in group 3 (presence of comorbidity plus IPSS Intermediate-2/High category) showed very low survival rates mainly because of unacceptably high CINRM. Our finding is similar to the results from a study of allogeneic HCT for AML and MDS, in which a group of patients with high HCT-CI scores and high disease risk showed the poorest survival rates. 25 In the study, CINRM in the highest risk group was lower after non-myeloablative as compared with myeloablative conditioning. Optimal intensity of the conditioning regimen before allogeneic HCT for MDS has not yet been standardized. Several retrospective studies have shown that reduced-intensity conditioning regimens resulted in lower CINRM compared with standard myeloablative regimens, but this benefit was offset by higher relapse rates. [39] [40] [41] Further efforts should be directed at optimization of conditioning regimen and effective prevention of GVHD. Incorporation of epigenetic therapy before or after transplantation should be also assessed.
Our study has some limitations mainly because of the nature of retrospective study and relatively small number of patients. Pre-transplant IPSS score was a significant risk factor for non-relapse mortality, but not for relapse, and this finding might be ascribed to the low incidence of relapse after HCT in our study population. Thus our findings, especially regarding the prognostic impact of pretransplant IPSS score, should be confirmed in a larger cohort of patients.
In conclusion, comorbidity and IPSS score at the time of HCT may stratify the risk of post transplant outcomes in MDS.
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